AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33115820 — intervention group
Group type: EXPERIMENTAL
Intervention: Lockdown period (20 days before and 20 days after lockdown)
Number of subjects: 130
Study 35067660 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-drop regimen of intracameral delivery of moxifloxacin and dexamethasone suspension and topical bromfenac for 30 days
Number of subjects: 30
Study 35067660 — intervention group
Group type: COMPARATOR
Intervention: 3-drop regimen of topical moxifloxacin 0.5% 4 times a day for 7 days, bromfenac 0.07% daily for 30 days, and prednisolone acetate 1% 4 times a day for 30 days
Number of subjects: 30
Study 35067660 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-drop regimen
Number of subjects: 30
Study 35067660 — intervention group
Group type: COMPARATOR
Intervention: 3-drop regimen
Number of subjects: 30
Study 34275159 — intervention group
Group type: EXPERIMENTAL
Intervention: Consented police disclosure (requires a report if the victim consents)
Number of subjects: 1045
Study 34275159 — intervention group
Group type: COMPARATOR
Intervention: Compelled police disclosure (requires a report regardless of victim consent)
Number of subjects: 1045
Study 32567522 — intervention group
Group type: EXPERIMENTAL
Intervention: Rat nerve growth factor combined with vitamin B
Number of subjects: 60
Study 32567522 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 35871496 — intervention group
Group type: EXPERIMENTAL
Intervention: High APTT group
Number of subjects: 844
Study 35871496 — intervention group
Group type: COMPARATOR
Intervention: Normal APTT group
Number of subjects: 844
Study 34052163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrospacing technique (HST)
Number of subjects: 54
Study 35019176 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐PRP/PAS
Number of subjects: 392
Study 35019176 — intervention group
Group type: COMPARATOR
Intervention: P‐PAS
Number of subjects: 392
Study 35019176 — intervention group
Group type: COMPARATOR
Intervention: P‐P
Number of subjects: 392
Study 33611360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostility measured at baseline using the MAACL
Number of subjects: 2321
Study 32701823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Number of subjects: 565
Study 32701823 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir (DTG)+F/TAF
Number of subjects: 565
Study 36106312 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.3% ropivacaine (Group L)
Number of subjects: 54
Study 36106312 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.5% ropivacaine (Group H)
Number of subjects: 54
Study 33421048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pack applied for 10 minutes (Group 1)
Number of subjects: 60
Study 33421048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pack applied for 12 minutes (Group 2)
Number of subjects: 60
Study 33421048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pack applied for 15 minutes (Group 3)
Number of subjects: 60
Study 33421048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pack applied for 20 minutes (Group 4)
Number of subjects: 60
Study 33338661 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized surfactant (AS)
Number of subjects: 149
Study 32556606 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic tracking and electrocardiography-guided catheter tip confirmation system (TCS)
Number of subjects: 210
Study 32556606 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 210
Study 36334528 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice change intervention
Number of subjects: 5694
Study 34444999 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 150 min per week of supervised moderate aerobic exercise (60–65% of VO2peak)
Number of subjects: 24
Study 34444999 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - maintained their daily routine
Number of subjects: 24
Study 34444999 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 24
Study 32916792 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus supervised exercise program
Number of subjects: 30
Study 32916792 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 36160161 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifrequency bioimpedance spectroscopy (BIS)
Number of subjects: 34
Study 36160161 — intervention group
Group type: COMPARATOR
Intervention: Control (clinical assessment plus single-frequency bioimpedance)
Number of subjects: 34
Study 36160161 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 36160161 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 34
Study 33596494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic treatment regime (1 g Giloy Ghanvati, 2 g Swasari Ras, 0.5 g Ashwagandha, 0.5 g Tulsi Ghanvati, and 4 drops of Anu taila)
Number of subjects: 100
Study 33596494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-looking tablets and drops)
Number of subjects: 100
Study 35881396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep health literacy program (2-week classroom curriculum for children, 1-hour parent workshop, and 1-on-1 parent discussions)
Number of subjects: 519
Study 35881396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep health literacy program
Number of subjects: 519
Study 33952584 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma patients during COVID-19 lockdown
Number of subjects: 0
Study 33952584 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma patients
Number of subjects: 0
Study 34695064 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) 150 mg/kg
Number of subjects: 10
Study 34695064 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 10
Study 32469850 — intervention group
Group type: EXPERIMENTAL
Intervention: Study intervention group (not specified)
Number of subjects: 0
Study 32469850 — intervention group
Group type: COMPARATOR
Intervention: Comparator (control group, not specified)
Number of subjects: 0
Study 35687709 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAR communication mode
Number of subjects: 239
Study 35687709 — intervention group
Group type: COMPARATOR
Intervention: Traditional communication mode
Number of subjects: 239
Study 32133462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 15
Study 32133462 — intervention group
Group type: COMPARATOR
Intervention: Apple juice
Number of subjects: 15
Study 36308611 — intervention group
Group type: COMPARATOR
Intervention: Blind insertion manoeuvre
Number of subjects: 60
Study 36308611 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-down optimized glottic exposure manoeuvre
Number of subjects: 60
Study 33585896 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 × 150 mg/day)
Number of subjects: 20
Study 33585896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 × 150 mg/day)
Number of subjects: 20
Study 36087309 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 5988
Study 33648632 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdosing of psychedelics for 4 weeks
Number of subjects: 191
Study 33648632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 33648632 — intervention group
Group type: COMPARATOR
Intervention: Microdosing vs. Placebo
Number of subjects: 191
Study 32069044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fused thioacene with 8 aromatic rings
Number of subjects: 250000
Study 32069044 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounds with the lowest 130 reorganization energy
Number of subjects: 250000
Study 32069044 — intervention group
Group type: COMPARATOR
Intervention: Dinaphthothienothiophene (DNTT)
Number of subjects: 250000
Study 33954783 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU of vitamin D3
Number of subjects: 221
Study 33954783 — intervention group
Group type: EXPERIMENTAL
Intervention: 3750 IU of vitamin D3
Number of subjects: 221
Study 32358383 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM)
Number of subjects: 204
Study 32358383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 34852695 — intervention group
Group type: EXPERIMENTAL
Intervention: NnEx (extract from sun dried Nelumbo nucifera leaves)
Number of subjects: 60
Study 34852695 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 60
Study 33857051 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration model intervention
Number of subjects: 72
Study 34774538 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC) 15 g per day
Number of subjects: 16
Study 34774538 — intervention group
Group type: COMPARATOR
Intervention: Control (emulsifier-free diet)
Number of subjects: 16
Study 32925495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Calorie Diet (LCD)
Number of subjects: 25
Study 32925495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Calorie Diet + Interval Exercise (LCD + INT)
Number of subjects: 25
Study 35101860 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led educational intervention
Number of subjects: 18554
Study 35101860 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 18554
Study 34537057 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 125 mg weekly
Number of subjects: 80
Study 34537057 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 80
Study 34537057 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept in SE-positive patients
Number of subjects: 80
Study 34537057 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab to abatacept switch group
Number of subjects: 80
Study 34537057 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept non-switch group
Number of subjects: 80
Study 32674351 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted conditioning activity (CA) with 5% of body mass external load
Number of subjects: 16
Study 32674351 — intervention group
Group type: COMPARATOR
Intervention: Resisted conditioning activity (CA) with 5% of body mass external load
Number of subjects: 16
Study 36235849 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including 23 interactive classroom workshops, 10 cross‐curricular activities, 13 homework challenges, visual exposure with educational posters, parent education via website, new dishes in school food system.
Number of subjects: 681
Study 36235849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 681
Study 33653810 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher lifetime amount of smoking
Number of subjects: 248
Study 33653810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever having smoked regularly
Number of subjects: 248
Study 32107817 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp social group intervention (n = 504)
Number of subjects: 1008
Study 32107817 — intervention group
Group type: COMPARATOR
Intervention: Short messages control group (n = 504)
Number of subjects: 1008
Study 35378224 — intervention group
Group type: EXPERIMENTAL
Intervention: Grey-white ratio (GWR) reported by radiologist
Number of subjects: 427
Study 35378224 — intervention group
Group type: COMPARATOR
Intervention: Secondary endpoints (APACHE IV score, Cerebral Performance Categories, Glasgow Coma Scale, GWR-stratified 1-year survival, RAND-36)
Number of subjects: 427
Study 34389567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lekker Fit! intervention
Number of subjects: 0
Study 34389567 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 0
Study 36053566 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal (PTU) rotary files
Number of subjects: 56
Study 36053566 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Next (PTN) rotary files
Number of subjects: 56
Study 36053566 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Gold (PTG) rotary files
Number of subjects: 56
Study 36053566 — intervention group
Group type: COMPARATOR
Intervention: Control group (not instrumented)
Number of subjects: 56
Study 33705695 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreduction followed by chemotherapy (six 3-weekly cycles of intravenous paclitaxel [175 mg/m2] or docetaxel [75 mg/m2] combined with intravenous carboplatin [AUC 5 mg/mL per min])
Number of subjects: 357
Study 33705695 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (no surgery group)
Number of subjects: 357
Study 33705695 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreduction followed by chemotherapy
Number of subjects: 357
Study 33480986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multidomain intervention monitored with the My Active and Healthy Aging platform
Number of subjects: 101
Study 33480986 — intervention group
Group type: COMPARATOR
Intervention: General health advice (Control)
Number of subjects: 101
Study 33991996 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 0.25 mg/kg
Number of subjects: 61
Study 33991996 — intervention group
Group type: COMPARATOR
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 61
Study 33991996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled together
Number of subjects: 61
Study 33991996 — intervention group
Group type: EXPERIMENTAL
Intervention: High trait dissociation
Number of subjects: 61
Study 32363775 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Illness Conversation Guide (SICG)
Number of subjects: 163
Study 36318025 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin with clavulanate for one week before surgery
Number of subjects: 60
Study 36318025 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (Control)
Number of subjects: 60
Study 33394268 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth
Number of subjects: 264
Study 33394268 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct exercise supervision
Number of subjects: 264
Study 33394268 — intervention group
Group type: COMPARATOR
Intervention: Control (brief education)
Number of subjects: 264
Study 33394268 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth vs. Direct
Number of subjects: 264
Study 33394268 — intervention group
Group type: COMPARATOR
Intervention: Telehealth vs. Control
Number of subjects: 264
Study 33394268 — intervention group
Group type: COMPARATOR
Intervention: Direct vs. Control
Number of subjects: 264
Study 33394268 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct
Number of subjects: 264
Study 33394268 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 264
Study 33514447 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief problem solving therapy (PST) delivered in four sessions over a maximum period of eight weeks
Number of subjects: 50
Study 33514447 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 50
Study 33514447 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief problem solving therapy (PST)
Number of subjects: 50
Study 33514447 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal outcomes
Number of subjects: 50
Study 32214298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine 10 mg/kg
Number of subjects: 62
Study 32214298 — intervention group
Group type: COMPARATOR
Intervention: Nebulized ketamine 3 mg/kg
Number of subjects: 62
Study 35506515 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (n=188)
Number of subjects: 382
Study 35506515 — intervention group
Group type: COMPARATOR
Intervention: Standard tracheostomy (control group, n=194)
Number of subjects: 382
Study 33877311 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus alisertib
Number of subjects: 174
Study 33877311 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 174
Study 36457091 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% pilocarpine mouthwash
Number of subjects: 48
Study 36457091 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pilocarpine mouthwash
Number of subjects: 48
Study 36457091 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 48
Study 33034099 — intervention group
Group type: EXPERIMENTAL
Intervention: Althaea officinalis 1% ointment
Number of subjects: 22
Study 33034099 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1% ointment
Number of subjects: 22
Study 35426510 — intervention group
Group type: COMPARATOR
Intervention: Q-NMES (Quadriceps Neuromuscular Electrical Stimulation)
Number of subjects: 11
Study 35426510 — intervention group
Group type: EXPERIMENTAL
Intervention: QG-NMES (Quadriceps and Gluteal Neuromuscular Electrical Stimulation)
Number of subjects: 11
Study 35426510 — intervention group
Group type: COMPARATOR
Intervention: Q-NMES at 20% of MVC
Number of subjects: 11
Study 35426510 — intervention group
Group type: EXPERIMENTAL
Intervention: QG-NMES at 20% of MVC
Number of subjects: 11
Study 34492731 — intervention group
Group type: EXPERIMENTAL
Intervention: Free intervention strategy for thalassemia screening and prenatal diagnosis offered to high-risk couples based on informed consent.
Number of subjects: 137222
Study 34492731 — intervention group
Group type: COMPARATOR
Intervention: Control group offered routine hematology examinations and selective testing for thalassemia mutations.
Number of subjects: 137222
Study 34492731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention strategy cost-effectiveness.
Number of subjects: 137222
Study 32347684 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance document recommendations on diagnosis and treatment of LGG patients
Number of subjects: 0
Study 37192722 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fat globule membrane + lactoferrin
Number of subjects: 292
Study 37192722 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 292
Study 33523702 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS delivered at Fp3 (10 mins at 1.5 mA)
Number of subjects: 168
Study 33523702 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (using a Face-Matching task)
Number of subjects: 168
Study 33523702 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at Fp3
Number of subjects: 168
Study 33523702 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 168
Study 32693427 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP)
Number of subjects: 15
Study 32693427 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo (PLA)
Number of subjects: 15
Study 35946416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 109
Study 35946416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I) + COPD Education (COPD‐ED)
Number of subjects: 109
Study 35946416 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 109
Study 35946416 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Education (COPD‐ED) + Attention Control (AC)
Number of subjects: 109
Study 35946416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I) + Attention Control (AC)
Number of subjects: 109
Study 35946416 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC) only
Number of subjects: 109
Study 34454260 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg)
Number of subjects: 21
Study 34454260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol (50 mg)
Number of subjects: 21
Study 34454260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 32580188 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (50 mg, n = 49; 70 mg, n = 50)
Number of subjects: 100
Study 603021098 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve M‐16V and Bifidobacterium longum BB536 supplementation
Number of subjects: 166
Study 603021098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bifidobacterial supplementation)
Number of subjects: 166
Study 603021098 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium supplementation
Number of subjects: 166
Study 33860689 — intervention group
Group type: EXPERIMENTAL
Intervention: Online ostracism
Number of subjects: 54
Study 33860689 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person ostracism
Number of subjects: 54
Study 33860689 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 54
Study 32433262 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline estradiol (E2) levels
Number of subjects: 4068
Study 32433262 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline estrone (E1) levels
Number of subjects: 4068
Study 32433262 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 levels by BMI < 25
Number of subjects: 4068
Study 32433262 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 levels by BMI > 30
Number of subjects: 4068
Study 32433262 — intervention group
Group type: EXPERIMENTAL
Intervention: E1 levels by BMI < 25
Number of subjects: 4068
Study 32433262 — intervention group
Group type: EXPERIMENTAL
Intervention: E1 levels by BMI > 30
Number of subjects: 4068
Study 32433262 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between E2 and E1
Number of subjects: 4068
Study 32433262 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in E2 and E1 levels
Number of subjects: 4068
Study 35134184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg with exenatide-matched placebo
Number of subjects: 64
Study 35134184 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide twice daily 10 µg with dapagliflozin-matched placebo
Number of subjects: 64
Study 35134184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin and exenatide
Number of subjects: 64
Study 35134184 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 64
Study 35134184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 64
Study 35134184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin-exenatide
Number of subjects: 64